Happel and Smith sued the Guilford County Board of Education and an organization of physicians who helped operate the school ...

We are neither stunned nor surprised that members of a new West Virginia legislative committee, chaired by Sen. Brian Helton, R-Fayette, want to order up yet another study, this one a year-long look ...

New therapeutic "cocktails" could offer long-lasting relief for treatment-resistant asthma and other inflammatory diseases of ...

That era might now be over. In recent years, the U.S. had already begun to neglect its public-health infrastructure, ...

TB kills more than a million people each year. Dr. Mireille Kamariza has spent her career developing better detection and ...

A study in the journal Diabetes Technology & Therapeutics (DTT) concludes that inhaled technosphere insulin (TI-Afrezza) ...

Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...

Alnylam Pharmaceuticals' shares rose more than 10% on Friday after the drugmaker secured U.S. approval for its heart disease drug, setting the stage for the 23-year-old biotech's next phase of growth.

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.

Alnylam Pharmaceuticals' shares rose about 7% before the bell on Friday following U.S. approval for its drug for a rare and deadly heart disease, securing an entry into a market dominated by Pfizer's ...

Policymakers must work tirelessly to prevent kids from beginning drug use and help people with addiction to achieve ...